Kara L Davis, DO
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Davis’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
Medicaid work
$7,872 in 2018
Medicaid paid $7,872 for 111 billed services this clinician did in 2018, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 111 | $7,872 |
| 2018 | 111 | 1 | 15 | $7,872 |
Money from drug and device companies
$3,473 in 2025
| 2025 | 1 | 2 | $3,348 | $3,473 |
| 2023 | 1 | 1 | $625 | $625 |
| 2021 | 1 | 1 | $2,440 | $2,440 |
| 2019 | 1 | 1 | None | $61 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Rylaze | $3,473 | 2 payments
|
See all 2 published payments
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-12-17 | Rylaze | $3,348 |
| Jazz Pharmaceuticals | Meals · 2025-12-05 | Rylaze | $125 |
See earlier years (2023, 2021, 2019)
2023: $625
| Novartis Pharmaceuticals | None | $625 | 1 payment
|
2021: $2,440
| Novartis Pharmaceuticals | Kymriah | $2,440 | 1 payment
|
2019: $61
| Novartis Pharmaceuticals | Kymriah | $61 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2024 | Their institution | $279,791 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2020 | Their institution | $203,321 |
| JAZZ PHARMACEUTICALS INC. · Assessing Cell Subtype-Specific Effects of Liposomal Cytarabine and Daunorubicin (Cpx-351) in Acute Myeloid Leukemia · 2021 | Their institution | $137,253 |
| JAZZ PHARMACEUTICALS INC. · Assessing Cell Subtype-Specific Effects of Liposomal Cytarabine and Daunorubicin (Cpx-351) in Acute Myeloid Leukemia · 2019 | Their institution | $106,752 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2021 | Their institution | $93,959 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2023 | Their institution | $65,527 |
| JAZZ PHARMACEUTICALS INC. · Assessing Cell Subtype-Specific Effects of Liposomal Cytarabine and Daunorubicin (Cpx-351) in Acute Myeloid Leukemia · 2020 | Their institution | $61,001 |
| Novartis Pharmaceuticals Corporation · Phase II Pediatric Relapsed and Or Refractory All Confirmatory · 2020 | Their institution | $43,656 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2025 | Their institution | $37,798 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2024 | Their institution | $36,232 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Trial To Determine the Efficacy and Safety of Ctl019 in Pediatric Patients With Relapsed and Refractory B Cell Acute Lymphoblastic Leukemia · 2020 | Their institution | $30,608 |
| Novartis Pharmaceuticals Corporation · A Phase II, Open Label, Multi-Center Trial To Determine the Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Aya Patients With An Early Loss of B-Cell Aplasia · 2021 | Their institution | $29,043 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2022 | Their institution | $26,724 |
| Novartis Pharmaceuticals Corporation · A Multicenter Study of Apheresis Collection of Peripheral Blood Mononuclear Cells Pbmc in Patients With Cd19 Expressing Malignancies Who Could Be Eligible for A Ctl019 Clinical Research Trial · 2019 | Their institution | $25,530 |
| Becton, Dickinson and Company · Bdb Iss 2022 Rfp - Acute Lymphoblastic Leukemia · 2023 | Their institution | $21,204 |
| AbbVie Inc. · Venclexta · 2020 | Their institution | $16,627 |
| Novartis Pharmaceuticals Corporation · Phase II Pediatric Relapsed and Or Refractory All Confirmatory · 2019 | Their institution | $8,637 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2023 | Their institution | $7,160 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Trial To Determine the Efficacy and Safety of Ctl019 in Pediatric Patients With Relapsed and Refractory B Cell Acute Lymphoblastic Leukemia · 2019 | Their institution | $4,790 |
| Novartis Pharmaceuticals Corporation · Phase II Pediatric Relapsed and Or Refractory All Confirmatory · 2023 | Their institution | $4,160 |
| Novartis Pharmaceuticals Corporation · A Phase II, Open Label, Multi-Center Trial To Determine the Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Aya Patients With An Early Loss of B-Cell Aplasia · 2022 | Their institution | $3,280 |
| Novartis Pharmaceuticals Corporation · Phase II Pediatric Relapsed and Or Refractory All Confirmatory · 2021 | Their institution | $2,798 |
| Novartis Pharmaceuticals Corporation · Phase II Pediatric Relapsed and Or Refractory All Confirmatory · 2022 | Their institution | $1,350 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Trial in First Line High Risk Hr Pediatric and Young Adult Patients With Bcell Acute Lymphoblastic Leukemia All Who Are Minimal Residual Disease Mrd Positive at End of Consolidation Eoc Therapy · 2019 | Their institution | $1,165 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2022 | Their institution | $180 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2025 | Their institution | $120 |
| AbbVie, Inc. · Venclexta · 2019 | Their institution | $63 |
Professional record
- NPI
- 1174647507
- Licence
- CA 20A10098
- Trained
- Philadelphia College of Osteopathic Medicine, 2004
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 1000 Welch Rd, Suite 300, Palo Alto, CA, 94304
- NPI first listed
- 2007-03-19
- NPI last updated
- 2010-07-19
This is when the NPI record was last certified, not a medical board exam.